- Companies
- Havea
Havea Acquisition, Valuation, Funding & Investors
Havea was acquired by BC Partners for $1.2B in June 2022, a 5.1x multiple on $229M of revenue.
Havea acquisition price
$1.2B
Acquired by BC Partners · Jun 2022
Havea revenue at acquisition
$229M
Last twelve months · Jun 2022
Havea revenue multiple at acquisition
5.1x
EV/Revenue · Jun 2022
Cumulative funding Havea raised
$191M
across 1 funding round
About Havea
Havea is a Nantes-area group manufacturing natural health supplements and cosmetics, owning Ponroy Santé founded in 1975 in Boufféré, France. The portfolio includes brands like Biolane infant nutrition, Vitarmonyl vitamins, and Yves Ponroy slimming aids, sold via pharmacies, supermarkets, and e-commerce in 20 countries. Havea produces probiotics, menopause relief, and organic skincare from three French plants serving 10 million consumers yearly.
Founded
1975
HQ
Website
Status
Acquired
Customer focus
B2C
Revenue model
Product sales
Revenue
$181M (Nov 2016)
Valuation
$1.2B (acquired Jun 2022)
Havea Acquisition
Havea was acquired by BC Partners for $1.2B on 23 June 2022.
The acquisition price implies a 5.1x revenue multiple on $229M of revenue.
Before the acquisition Havea had raised $191M across 1 funding round.
Havea is a France-based leading European natural healthcare group, formerly Ponroy Santé, operating five strategic brands: Vitavea (everyday food supplements), Aragan (premium food supplements), Biolane (baby care), Dermovitamina (skin care), and Densmore (ophthalmology and gynaecology). The company manufactures most products in Boufféré, France, employs over 800 people, and has delivered above-market organic growth through end-to-end value chain coverage, omnichannel distribution, and sell-in/sell-out strategies. BC Partners entered exclusive negotiations on June 23, 2022, to acquire a majority stake from 3i Group and Cathay Capital, with the deal completing in October 2022 alongside management and PSP Investments. Since 3i's 2017 investment, Havea doubled in size with double-digit organic growth, five acquisitions reinforcing presence in Italy and Belgium, brand portfolio simplification, and multichannel strategies including D2C subscriptions. The sale provided 3i a circa 50% uplift to its March 2022 valuation. The partnership aims to support Havea's organic growth, accelerate M&A, and invest in digitalisation, leveraging structural tailwinds in natural healthcare, preventative care, and patient value.
| Acquirer | Date | Type | Price | EV/Revenue |
|---|---|---|---|---|
| 23 Jun 2022 | PE buyout | $1.2B | 5.1x |
Havea Revenue
Havea's latest recorded revenue is $181M, as of its undisclosed-stage round in November 2016.
Havea revenue by funding round
| Date | Revenue * | Stage |
|---|---|---|
| Nov 2016 | $181M | Undisclosed stage |
* Revenue (or ARR) figures are the values recorded alongside each funding round. Typically run-rate revenue at the time of the deal, or a reported LTM (last 12 months) revenue.
Havea Funding History
Havea has raised a total of $191M across 1 funding round.
Havea funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Nov 2016 | Undisclosed stage | 3i Group (lead); Cathay Capital | $191M | 3i Group and Cathay Capital invested in Ponroy Santé, the French natural healthcare group now called Havea, in November 2016 alongside the company's management. The combined equity investment was EUR 180 million, made up of EUR 150 million from 3i, which led the transaction, and EUR 30 million from Cathay Capital, with a debt package provided by a bank syndicate including Natixis, BNP Paribas, Societe Generale, Bank of Ireland, ING and HSBC. At the time the business reported EBITDA of EUR 25 million on sales of EUR 170 million. Ponroy Santé is a consumer and patient healthcare group selling food supplements and other natural health products, with a presence in France, Italy and Belgium. After the investment the group pursued a buy-and-build strategy, adding Ersa's Aragan and Synactifs brands in 2017, Densmore in 2018 and Pasquali Healthcare in 2019. The group was later renamed Havea and was sold to BC Partners in 2022. |
Who has invested in Havea?
2 investors have backed Havea across its funding rounds, including Cathay Capital and 3i Group.
Lead investors include 3i Group.
Havea Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
This data is available for Pro users. Sign up to see all 2 Havea investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAcquisitions by Havea
Havea has acquired 9 companies to date.
Last acquisition by Havea was on February 2nd 2023. Havea acquired Biocyte for undisclosed valuation.
Latest Acquisitions by Havea
| Description | Biocyte is a Monaco-based laboratory specializing in premium nutritional supplements for beauty, anti-aging, slimming, and wellness. Founded in 2008, it formulates high-dosage products with exclusive natural ingredients targeting skin health and longevity mechanisms, available in pharmacies across France and Europe. | Bears with Benefits is a Berlin-based producer of vegan beauty supplements in gummy form. Its product line includes biotin hair gummies, collagen skin boosters, and sleep aids with ashwagandha and melatonin. Sold online across Europe, the supplements use pectin base and natural flavors. Founded in 2020, the company sources ingredients from Germany and exports to the UK and Netherlands. | ixX pharma is a Belgian contract manufacturer of private-label nutritional supplements, producing vitamin, mineral, and herbal capsules in GMP-certified facilities near Brussels. Product lines include multivitamins, omega-3s, and probiotics for pharmacies and e-commerce brands across Europe, with annual capacity exceeding 100 million units. | Laudavie is a French consumer healthcare company whose brands include Calmosine, a specialist in food supplements for infants and children. Its products are sold through pharmacies and address digestive comfort and sleep in babies and young children. | |
| HQ Country | |||||
| HQ City | Nice | Grünwald | Nieuwkerken-Waas | Paris | |
| Deal Date | 2 Feb 2023 | 9 Nov 2022 | 1 Sep 2021 | 7 Jan 2021 | |
| Valuation | undisclosed | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Havea acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Havea Competitors
Havea competitors include listed companies like Jamieson Wellness, Procter & Gamble Health, Mega Lifesciences and Zydus Wellness, and private ones like KOS and L&P Cosmetic.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $587M | $94M | $1.4B | 2.6x | ||
| Publicly listed | $147M | $49M | $978M | 6.4x | ||
| Publicly listed | $422M | $82M | $917M | 1.9x | ||
| Publicly listed | $419M | $50M | $1.6B | 3.7x | ||
| Private | $498M | $83M | $729M | 1.5x | ||
| Private | - | - | $1.1B | - |
Havea Public Comps
Havea is no longer listed, but its public comps include Chicmax Cosmetic, EID Parry India, BioGaia, Edgewell, Natura Cosmeticos, SILICON2, Chengzhi, Procter & Gamble Health, Jamieson Wellness and Jubilant Ingrevia.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $1.4B | $237M | 0.9x | 0.9x | 5.1x | 9.5x | |||
| $2.9B | $324M | 0.8x | 0.6x | 7.5x | 6.7x | |||
| $157M | $44M | 7.7x | 7.0x | 27.2x | 22.5x | |||
| $2.2B | $186M | 1.0x | 1.1x | 11.7x | 8.6x | |||
| $4B | $334M | 0.5x | 0.5x | 6.3x | 4.2x | |||
| $825M | $171M | 1.6x | 1.2x | 7.8x | 6.2x | |||
| $1.7B | $130M | 1.1x | 1.1x | 14.2x | - | |||
| $147M | $49M | 6.4x | 6.4x | 19.1x | 19.7x | |||
This data is available for Pro users. Sign up to see all Havea competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Havea
| When was Havea founded? | Havea was founded in 1975. |
| Where is Havea headquartered? | Havea is headquartered in Nantes, France. |
| Is Havea publicly listed? | No, Havea was acquired by BC Partners in June 2022. |
| Who acquired Havea? | Havea was acquired by BC Partners in June 2022. |
| How much was Havea acquired for? | Havea was acquired for $1.2B in June 2022, a 5.1x revenue multiple. |
| How much funding has Havea raised? | Havea has raised $191M across 1 funding round. |
| What was Havea's last funding round? | Havea's last funding round was a $191M undisclosed-stage round in November 2016, led by 3i Group. |
| Who are Havea's investors? | Havea's investors include 3i Group and Cathay Capital. |
| What is Havea's revenue? | Havea's latest recorded revenue is $181M (November 2016). |
| Which companies are comparable to Havea? | Companies comparable to Havea include Jamieson Wellness, Procter & Gamble Health, Mega Lifesciences, Zydus Wellness, KOS and L&P Cosmetic. |
| How many companies has Havea acquired? | Havea has acquired 9 companies, including Biocyte, Bears with Benefits, ixX pharma, Laudavie and Pasquali Healthcare. |
See companies similar to Havea
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




